ZCA
BCTX

Zeke Capital Advisors’s Briacell Therapeutics BCTX Stock Holding History

Zeke Capital Advisors’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-300
Closed -$174K – 335
2021
Q1 		$174K Buy
+300
New +$163K 0.01% 284

Other funds holding BCTX

ACM
Altium Capital Management New York $42M AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return

Zeke Capital Advisors's BCTX Position: Q2 2021 in Review

Zeke Capital Advisors sold out of Briacell Therapeutics (BCTX) in Q2 2021, closing a stake of 300 shares — an estimated $174K sold.

Zeke Capital Advisors first reported a position in BCTX in Q1 2021 and held it in 1 quarter. The position peaked at $174K in Q1 2021. 22 funds tracked by Wall St. Rank hold BCTX as of Q2 2021.

  • Zeke Capital Advisors reported no remaining Briacell Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Zeke Capital Advisors sold 300 Briacell Therapeutics shares in Q2 2021, an estimated $174K.
  • Zeke Capital Advisors first reported a position in Briacell Therapeutics in Q1 2021 and held it in 1 quarter.
  • Zeke Capital Advisors's Briacell Therapeutics position peaked at $174K in Q1 2021.
  • 22 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2021.

Based on Zeke Capital Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.